PROpel and MAGNITUDE Trials for mCRPC

Tanya Dorff, MD, Associate Professor in the Department of Medical Oncology & Therapeutics Research, and Section Chief of the Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, provides an overview of the latest data for PARP inhibitor plus androgen receptor-targeted agents for patients with mCRPC.